POZ™- The Next Generation of Polymer Therapeutics Serina Therapeutics, Inc. has developed a proprietary drug delivery polymer technology based upon the polymer poly(2-oxazoline), or POZ™. We are developing a pipeline of proprietary and partnered programs applying this platform to cancer, pain, refractory epilepsy, and movement disorders such as Parkinson’s disease and restless leg syndrome. Who …
Employees: 11-50
Total raised: $19.5M
Founded date: 2007
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.12.2024 | - | $10M | - |
| 01.06.2011 | - | $9.5M | - |
Mentions in press and media 4
| Date | Title | Description |
| 04.12.2024 | Serina Therapeutics Raises $10M in Financing | Serina Therapeutics (NYSE American: SER), a Huntsville, AL-based clinical-stage biotechnology company, raised $10M in funding. The round was led by JuvVentures (UK) Limited. Under the terms of the funding agreement, Serina will issue one mi... |
| 09.10.2012 | Once-weekly drug for Parkinson’s disease symptoms could reach clinical trials in 2013 | There’s no cure for Parkinson’s disease; current treatment regimens focus on managing the most disruptive motor symptoms. They often include drugs that convert into dopamine in the brain, mimic the effects of dopamine or block the breakdown... |
| 01.06.2011 | Serina Therapeutics Closes $9.5M Financing Round | Serina Therapeutics, Inc., a Huntsville, Ala.-based pharmaceutical company that is advancing novel therapeutics for cancer, inflammation, pain and metabolic disorders using its proprietary polymer technology, has closed a $9.5m financing ro... |
| - | Once-weekly drug for Parkinson’s disease symptoms could reach clinical trials in 2013 | A drug for Parkinson’s disease that could ease some of the complications associated with current dopamine replacement therapies could reach clinical trials next year. Serina Therapeutics’ platform technology is based on the polymer polyoxaz... |